Despite significant advances in recent years, treatment of metastatic malignancies remains a significant challenge. There is an urgent need for development of novel therapeutic approaches. Virotherapy approaches have considerable potential, and among them measles virus (MV) vaccine strains have emerged as a promising oncolytic platform. Retargeted MV strains deriving from the Edmonston vaccine lineage (MV-Edm) have shown comparable antitumor efficacy to unmodified strains against receptor expressing tumor cells with improved therapeutic index. Here, we describe the construction, rescue, amplification, and titration of fully retargeted MV-Edm derivatives displaying tumor specific receptor binding ligands on the viral surface in combination with H protein CD46 and SLAM entry ablating mutations.
CITATION STYLE
Msaouel, P., Iankov, I. D., Allen, C., Russell, S. J., & Galanis, E. (2012). Oncolytic measles virus retargeting by ligand display. In Methods in Molecular Biology (Vol. 797, pp. 141–162). Humana Press Inc. https://doi.org/10.1007/978-1-61779-340-0_11
Mendeley helps you to discover research relevant for your work.